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Epidemiological studies have examined breast cancer risk in relation to sex hormone concentrations
measured by different methods: ‘‘extraction’’ immunoassays (with prior puriﬁcation by organic solvent
extraction, with or without column chromatography), ‘‘direct’’ immunoassays (no prior extraction or col-
umn chromatography), and more recently with mass spectrometry-based assays. We describe the asso-
ciations of estradiol, estrone and testosterone with both body mass index and breast cancer risk in
postmenopausal women according to assay method, using data from a collaborative pooled analysis of
18 prospective studies. In general, hormone concentrations were highest in studies that used direct
assays and lowest in studies that used mass spectrometry-based assays. Estradiol and estrone were
strongly positively associated with body mass index, regardless of the assay method; testosterone was
positively associated with body mass index for direct assays, but less clearly for extraction assays, and
there were few data for mass spectrometry assays. The correlations of estradiol with body mass index,
estrone and testosterone were lower for direct assays than for extraction and mass spectrometry assays,
suggesting that the estimates from the direct assays were less precise. For breast cancer risk, all three
hormones were strongly positively associated with risk regardless of assay method (except for testoster-
one by mass spectrometry where there were few data), with no statistically signiﬁcant differences in the
trends, but differences may emerge as new data accumulate. Future epidemiological and clinical research
studies should continue to use the most accurate assays that are feasible within the design characteristics
of each study.
 2014 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Introduction
Prospective epidemiological studies of the relationships of
endogenous estrogens and other sex hormones with the risk for
breast cancer and other diseases have used a variety of assays to
measure hormone concentrations in stored samples of serum or
plasma. Results have now been published from 20 such studies
since the late 1980s. The ﬁrst such studiesmeasured hormoneswith
in-house radioimmunoassays, which generally used a relatively
large volume of sample and incorporated an organic extraction step
and usually also puriﬁcation by column chromatography. In the1990s and 2000s the use of commercially produced immunoassays
without extraction or chromatography (‘‘direct assays’’) became
popular with many epidemiologists because these assays were
easier to perform (and therefore faster and cheaper) and use less
sample than the extraction assays. Some of the direct assays
provided results considered adequate for epidemiological studies,
which seek mainly to rank individuals rather than to provide
accurate estimates of hormone concentrations [1], but the direct
methods tend to overestimate concentrations and suffer from
cross-reactivity with other steroids [2–5]. More recentlymass spec-
trometry methods have been developed to measure sex hormones.
However, the effect of these assay differences on the associations
of sex hormones with other factors is unclear.
The aim of this paper is to describe the relationships of
circulating estradiol, estrone and testosterone in postmenopausal
women with body mass index (BMI) and breast cancer risk
according to the typeof assayused, usingdata fromthe international
Endogenous Hormones and Breast Cancer Collaborative Group [6].
These analyses were prepared for presentation at the workshop
50 Endogenous Hormones and Breast Cancer Collaborative Group / Steroids 99 (2015) 49–55‘‘Measuring Estrogen Exposure andMetabolism’’ in Bethesda,Mary-
land, March 2014.2. Methods
2.1. Data collection
Studies were eligible for the collaborative re-analysis if they
included data on endogenous hormones and breast cancer risk
using prospectively collected blood samples from postmenopausal
women, as described previously [6–8]. Studies were identiﬁed by
computer-aided literature searches, within relevant review arti-
cles, and through discussions with colleagues. The studies included
were: Breast and Bone Follow-up to the Fracture Intervention Trial
(BFIT), USA [9]; CLUE I study ‘‘Give us a clue to cancer and heart
disease’’; Washington County, MD, USA [10]; Cancer Prevention
Study-II Nutrition Cohort (CPS-II Nutrition Cohort), USA [11];
Columbia Missouri Serum Bank, MO, USA [12,13]; European
Prospective Investigation into Cancer and Nutrition (EPIC), Europe
[14]; Guernsey, UK [15]; Malmö/Umeå, Sweden [16]; the
Melbourne Collaborative Cohort Study (MCCS), Australia [17]; the
Multi-Ethnic Cohort (MEC), USA [18]; Nurses’ Health Study (NHS
I), USA [19,20]; New York University Women’s Health Study
(NYU WHS), USA [21–23]; Study of Hormones and Diet in the
Etiology of Breast Tumors (ORDET), Italy [24]; Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial cohort (PLCO),
USA [25]; Rancho Bernardo, USA [26]; Radiation Effects Research
Foundation (RERF), Japan [27,28]; Study of Osteoporotic Fractures
(SOF), USA [29]; United Kingdom Collaborative Trial of OvarianTable 1
Age-adjusted geometric mean (95% CI) hormone concentrations for controls, by assay typ
Assay type and study Sample Estradiol (pmol/L)
N Mean (95% CI)
Extractiona
CLUE-I Serum 58 51.9 (44.3–60.8)
Guernsey Serum 177 37.5 (34.2–41.1)
MEC Plasma 302 30.1 (28.0–32.3)
NHS I Plasma 637 24.9 (23.8–26.2)
Rancho Bernardo Plasma 127 42.3 (38.0–47.1)
SOF Serum 365 21.2 (19.8–22.7)
Sweden Malmö/Umeå Plasma
Direct
Columbia (direct assay) Serum 133 48.4 (43.6–53.8)
EPIC phase 1 Serum 1152 91.5 (88.2–94.8)
EPIC phase 2 Serum 818 71.6 (68.6–74.7)
Guernsey Serum
MCCS Plasma 707 60.3 (57.6–63.1)
NYU WHS phase 1 Serum 558 84.7 (80.4–89.3)
NYU WHS phase 2 Serum
ORDET Serum 681 18.2 (17.4–19.1)
RERF phase 1 Serum 45 69.7 (58.3–83.5)
RERF phase 2 Serum 124 68.0 (61.0–75.8)
Sweden Malmö/Umeå Plasma
UKCTOCS Serum 375 59.4 (55.8–63.2)
WHI-OS Serum 436 41.1 (38.7–43.5)
Mass spectrometry
BFIT Serum 490 [40.0 (37.8–42.3)]b
CPS-II Nutrition Cohort 249 24.4 (22.5–26.4)
Columbia (mass spec.) Serum 217 11.8 (10.9–12.8)
PLCO Serum 445 15.9 (15.0–16.8)
Abbreviations for study names: BFIT = Breast and Bone Follow-up to the Fracture Inte
heart disease’’; CPS-II = Cancer Prevention Study-II; EPIC = European Prospective Invest
MEC = Multi-ethnic Cohort; NHS I = Nurses’ Health Study I; NYU WHS = New York Univer
Breast Tumors; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RE
UKCTOCS = United Kingdom Collaborative Trial of Ovarian Cancer Screening; WHI-OS =
a Assays which included an extraction step; all except two (Guernsey and Sweden M
b Geometric mean concentrations of estradiol and estrone for BFIT are for total sterCancer Screening (UKCTOCS), UK [30]; and the Women’s Health
Initiative, Observational Study (WHI-OS), USA [31]. Details of the
recruitment of participants, informed consent, and deﬁnitions of
reproductive variables are in the original publications. Women
who were using menopausal hormone therapy or other exogenous
sex hormones at the time of blood collection were excluded.
Collaborators provided data on concentrations of the hormones
estradiol, estrone and testosterone, where available, as well as data
on reproductive and anthropometric factors.2.2. Statistical analysis
For the analyses of hormones and BMI, hormone concentrations
were logarithmically transformed to normalize the distributions.
Geometric mean hormone concentrations by categories of BMI
(calculated as weight in kilograms divided by the square of height
in metres and categorized as <22.5, 22.5–24.9, 25.0–27.4, 27.5–29.9,
and 30.0+ kg/m2), together with their 95% conﬁdence intervals
(CIs), were calculated using the predicted values from analysis of
variance models, adjusted for study, age at blood collection (<55,
55–59, 60–64, 65–69, and 70+ years), and type of menopause
(natural, hysterectomywithout ovariectomy, bilateral ovariectomy,
other or unknown). Partial correlations of estradiol with estrone,
testosterone and BMI were computed using study-speciﬁc stan-
dardized values: (xjk mj)/sj where mj and sj denote the mean and
standard deviation of the log-transformed hormone concentrations
in study j and xjk is an observation from that study. These standard-
ized values were adjusted for age at blood collection and type of
menopause (same categories as above).e and study.
Estrone (pmol/L) Testosterone (nmol/L)
N Mean (95% CI) N Mean (95% CI)
58 134 (118–153)
303 118 (111–125) 303 0.79 (0.73–0.85)
623 90 (86–93) 626 0.74 (0.71–0.78)
131 109 (100–119) 128 0.78 (0.70–0.88)
245 72 (67–77) 372 0.62 (0.58–0.67)
230 1.17 (1.07–1.27)
133 120 (110–131) 133 0.55 (0.49–0.61)
1106 140 (136–145) 1319 1.14 (1.10–1.18)
575 140 (135–147) 808 1.10 (1.05–1.15)
178 0.93 (0.84–1.02)
714 0.66 (0.62–0.69)
562 95 (91–99) 562 0.63 (0.60–0.67)
347 98 (93–103)
681 0.78 (0.74–0.82)
126 0.37 (0.33–0.42)
239 73 (69–78)
381 302 (287–318) 377 0.83 (0.78–0.89)
490 [291 (277–305)]b
268 65 (61–69) 254 0.68 (0.63–0.74)
217 45 (42–48)
445 55 (53–58)
rvention Trial; CLUE = Washington County, MD study ‘‘Give us a clue to cancer and
igation into Cancer and Nutrition; MCCS = Melbourne Collaborative Cohort Study;
sity Women’s Health Study; ORDET = Study of Hormones and Diet in the Etiology of
RF = Radiation Effects Research Foundation; SOF = Study of Osteoporotic Fractures;
Women’s Health Initiative, Observational Study.
almö/Umeå) also included puriﬁcation by chromatography.
oids, versus unconjugated steroids in the other studies.
Fig. 1. Geometric mean estradiol (pmol/L, with 95% conﬁdence intervals) in postmenopausal control women by assay type in relation to BMI, adjusted for study, age at blood
collection and type of menopause.
Fig. 2. Geometric mean estrone (pmol/L, with 95% conﬁdence intervals) in postmenopausal control women by assay type in relation to BMI, adjusted for study, age at blood
collection and type of menopause.
Fig. 3. Geometric mean testosterone (nmol/L, with 95% conﬁdence intervals) in postmenopausal control women by assay type in relation to BMI, adjusted for study, age at
blood collection and type of menopause.
Endogenous Hormones and Breast Cancer Collaborative Group / Steroids 99 (2015) 49–55 51Logistic regression conditioned on study-speciﬁc matching vari-
ables and stratiﬁed by study was used to calculate the odds ratio
(OR) for breast cancer in relation to serum/plasma hormone con-
centrations, categorizing women in each study according to the
quintiles of hormone concentration for the controls in that study.
Adjustments were not made for reproductive, anthropometric or
lifestyle risk factors for breast cancer because hormones may
mediate the effects of some of these risk factors and previous anal-
yses have shown that adjustments for these risk factors do not
materially change the associations of hormones with breast cancer
risk in postmenopausal women [6,7]. Most of the original studies
used a nested case-control design with controls matched to cases
on age and date at blood collection and other relevant factors,and the original matching was retained in the current analyses.
Study-speciﬁc cut-points were used because the absolute concen-
trations of hormones vary substantially between studies, partly
due to laboratory variation and different assay methods [6]. Tests
for linear trend were calculated scoring the ﬁfths as 0, 0.25, 0.5,
0.75, and 1. Heterogeneity in linear trends between studies using
different assay methods was assessed using chi-square tests.
For the studies using mass spectrometry, we used the values for
unconjugated steroids, where available; for BFIT, the mass spec-
trometry data for estradiol and estrone were available for total ste-
roids, which sums the sulphated, glucuronidated, and unconjugated
forms, but not for unconjugated steroids, and are not included in the
analyses of steroids by BMI.
Table 2
Partial correlations of log estradiol with BMI, log estrone and log testosterone: values
standardized to study-speciﬁc distribution and adjusted for age and type of
menopause.
Assay BMI Estrone Testosterone
Extraction 0.42 0.66 0.40
Direct 0.19 0.38 0.32
Mass spectrometry 0.41 0.84 0.41
52 Endogenous Hormones and Breast Cancer Collaborative Group / Steroids 99 (2015) 49–55All statistical tests were two-sided, and statistical signiﬁcance
was taken as P < 0.05. All analyses were performed using Stata Sta-
tistical Software release 10 (Stata Corp., College Station, TX).
3. Results
3.1. Collaborating studies
Eighteen studies contributed data, eleven in the USA, two in the
UK, one each in Australia, Italy, Japan and Sweden, and the multi-
centre European study EPIC. Geometric mean hormone concentra-
tions in controls are shown in Table 1. For estradiol, six studies had
used extraction assays (of which all except Guernsey also used
puriﬁcation by column chromatography), ten studies had used
direct assays and four studies had used mass spectrometry assays.
Some studies had assay results from more than one phase of fol-
low-up, and in the Columbia study results were available from
an early phase of follow-up using direct assays, and from a later
time of follow-up using mass spectrometry assays (which included
some of the same women as the ﬁrst follow-up).
3.2. Associations of hormones with BMI
Figs. 1–3 show the geometric mean hormone concentrations in
relation to BMI for estradiol, estrone, and testosterone. Among all
controls for estradiol (Fig. 1) and estrone (Fig. 2), the mean values
were highest for the direct assays and lowest for the massFig. 4. Odds ratios (95% conﬁdence intervals) for breast cancer by ﬁfth of estradiol in
speciﬁc matching variables and stratiﬁed by study.spectrometry assays, with the extraction assays intermediate. For
all assay types the mean concentrations of both estrogens were
positively associated with BMI in an approximately linear fashion.
Geometric mean concentrations of estradiol were 82%, 31% and
43% higher in obese (BMIP 30) than in lean (BMI < 22.5) women
for data from extraction, direct and mass spectrometry assays,
respectively (Fig. 1); the corresponding differences for estrone
were 57%, 47% and 33% (Fig. 2). Geometric mean concentrations
of testosterone were 12% and 26% higher in obese (BMIP 30) than
in lean (BMI < 22.5) women for data from extraction and direct
assays, respectively, with few data from mass spectrometry
(Fig. 3). The correlations of estradiol with BMI, estrone and testos-
terone were substantially larger for extraction and mass spectrom-
etry assays than for direct assays (Table 2).3.3. Associations of hormones with breast cancer risk
Figs. 4–6 show the associations of the hormones with breast
cancer risk. With the exception of testosterone measured by mass
spectrometry, for which there was limited data, all measures of the
three hormones showed highly statistically signiﬁcant associations
with breast cancer risk, with odds ratios in the highest versus the
lowest ﬁfth between 1.46 and 2.66. There was no statistically sig-
niﬁcant heterogeneity between the different assay methods for the
linear associations of each hormone with breast cancer risk.4. Discussion
The ﬁndings from the different assay types (direct, extraction,
mass spectrometry) were broadly similar. For all three hormones
examined, the largest amount of data was from direct assays.
Where enough data were available, all three assay methods
showed that BMI was strongly positively associated with the estro-
gens and moderately positively associated with testosterone, and
all three hormones were strongly positively associated with breast
cancer risk, regardless of assay method.postmenopausal cases and matched controls by assay type, conditioned on study-
Fig. 5. Odds ratios (95% conﬁdence intervals) for breast cancer by ﬁfth of estrone in postmenopausal cases and matched controls by assay type, conditioned on study-speciﬁc
matching variables and stratiﬁed by study.
Fig. 6. Odds ratios (95% conﬁdence intervals) for breast cancer by ﬁfth of testosterone in postmenopausal cases and matched controls by assay type, conditioned on study-
speciﬁc matching variables and stratiﬁed by study.
Endogenous Hormones and Breast Cancer Collaborative Group / Steroids 99 (2015) 49–55 53The cross-sectional analyses of geometric mean hormone con-
centrations in relation to BMI showed that on average the direct
assays give concentrations that are substantially higher than those
from the other assay methods. This difference has been discussed
previously, and may be in part due to cross-reactivity between ste-
roids in the direct assays leading to estimated absolute concentra-
tions which may be greater than the true value [2–5]. The direct
assays still showed the expected strong positive associationsbetween BMI and estrogens, but the relative increase in estrogens
from lean to obese women was larger for the extraction assays
than for the other methods. Conversely the direct assays showed
a stronger positive association between testosterone and BMI than
the extraction assays. This could perhaps be due to cross-reactivity
with estrogenic compounds in the direct assay methods. The
correlations of estradiol with BMI, estrone and testosterone were
lower for the direct assays than for the extraction and mass
54 Endogenous Hormones and Breast Cancer Collaborative Group / Steroids 99 (2015) 49–55spectrometry assays; the reason for this is not known but might
again be due to cross-reactivity in the direct assay methods.
The relative risk analyses showed strong positive associations of
all three hormones with breast cancer risk, as previously reported
by this collaborative group [6] and by subsequent individual
studies [9,13,14,16,18,20,23,25,30,31]. There were no striking or
statistically signiﬁcant differences between the results from the
different assay methods, but this should be re-evaluated as
prospective data accumulate because further data from the more
accurate assay methods might reveal differences.
In conclusion, the existing data from prospective studies show
that estrogens are strongly associated with breast cancer risk,
regardless of the assay method. Direct assays are in general less
accurate than extraction assays or mass spectrometry assays
[2–5], and it is possible that the estrogen measures from direct
assays may partly reﬂect cross-reactivity with a number of
estrogens and the detection of overall estrogenicity. Recent
technological advances have made it possible to apply mass
spectrometry methods to small sample volumes in large-scale
studies, and future epidemiological and clinical research studies
should continue to use the most accurate assays that are feasible
within the design characteristics of each study.
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